The EU Commission clears a merger subject to remedies in the pharmaceutical sector (Boehringer Ingelheim / Sanofi)

KEYWORDS
References

EU Commission, Boehringer Ingelheim / Sanofi, Press Release, 4 August 2016

EU Commission, Boehringer Ingelheim / Sanofi, Case M.7919, 4 August 2016

MERGERS: COMMISSION CLEARS ACQUISITION OF BOEHRINGER INGELHEIM'S CONSUMER HEALTH BUSINESS BY SANOFI, SUBJEC TO CONDITIONS* The European Commission has approved under the EU Merger Regulation the proposed acquisition of the consumer health business of Germany's Boehringer Ingelheim by Sanofi of France, subject to conditions. Both companies are active in the pharmaceutical industry. The decision is conditional upon the divestment of a number of Sanofi's and Boehringer Ingelheim's businesses in the Czech Republic, Estonia, France, Hungary, Greece,

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • European Commission - DG COMP (Brussels)
    Belgium 1296 contributions 2705111 visits

Quotation

European Commission, The EU Commission clears a merger subject to remedies in the pharmaceutical sector (Boehringer Ingelheim / Sanofi), 4 August 2016, e-Competitions Pharma & Mergers, Art. N° 80704

Visites 317

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues